Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vutrisiran in hereditary transthyretin amyloidosis
NCT03759379Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2019
- Primary completion
- Nov 2020
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 22
01
Overview
A Phase 3 trial of vutrisiran in hereditary transthyretin amyloidosis (ATTRv), sponsored by Alnylam Pharmaceuticals. Started Feb 2019; status: completed.
02
Drugs
vutrisiran
03
Conditions
hereditary transthyretin amyloidosis (ATTRv)
Beyond the preview
Go deeper on NCT03759379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759379.